Bronchiectasis in Rheumatoid Arthritis: Report of Four Cases and a Review of the Literature-Implications for Management with Biologic Response Modifiers

Seminars in Arthritis and Rheumatism

Volumn 35, Issue 6, 2006, Pages 379-387

  Lieberman Maran, Lori ^a   Orzano, Irene M ^a   Passero, Michael A ^a   Lally, Edward V ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

Author keywords

bronchiectasis; clinical trials; infection; rheumatoid arthritis; safety; tumor necrosis factor inhibitors

Indexed keywords

ADALIMUMAB; CIPROFLOXACIN; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; TOBRAMYCIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BRONCHIECTASIS; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HUMAN; HYPOTENSION; INFECTION; LUNG DISEASE; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL RESPONSE MODIFIERS; BRONCHIECTASIS; CLINICAL TRIALS; FEMALE; HUMANS; MIDDLE AGED; PNEUMONIA;

EID: 33744810610     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.02.003     Document Type: Article

References (41)

1. Harris Jr. E.D. Course and complications of established rheumatoid arthritis. In: Harris Jr. E.D., Budd R.C., Firestein G.S., Genovese M.C., Sergent J.S., Ruddy S., et al. (Eds). Kelley's Textbook of Rheumatology. 7th (2005), Elsevier, Philadelphia, PA 1043-1076
2. Turesson C., O'Fallon W.M., Crowson C.S., Abriel S.E., and Matteson E.L. Occurrence of extraarticular disease manifestations is associated with excess mortality in a community-based cohort of patients with rheumatoid arthritis. J Rheumatol 29 1 (2002) 62-67
3. Turesson C., Fallon W.M., Crowson C.S., Gabriel S.E., and Matteson E.L. Extraarticular disease manifestations in rheumatoid arthritis. incidence trends and risk factors over 46 years. Ann Rheum Dis 62 (2003) 722-727
4. Anaya J.M., Diethelm L., Ortiz L.A., Gutierrez M., Citera G., Welsh R.A., et al. Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum 24 4 (1995) 242-254
5. Tanoue L.T. Pulmonary manifestations of rheumatoid arthritis. Clin Chest Med 19 4 (1998) 667-686
6. Aronoff A., Waters E.G.L., and Fearnley G.R. Lung lesions in rheumatoid arthritis. BMJ (1955) 228-232
7. Bamji A., and Cooke N. Rheumatoid arthritis and chronic bronchial suppuration. Scand J Rheumatol 14 (1985) 15-21
8. Solanki T., and Neville E. Bronchiectasis and rheumatoid disease. is there an association?. Br J Rheumatol 31 (1992) 691-693
9. McMahon M.J., Swinson D.R., Shettar S., Wolstenholme R., Chattopadhyay C., Smith P., et al. Bronchiectasis and rheumatoid arthritis. a clinical study. Ann Rheum Dis 52 (1993) 776-779
10. Shadick N.A., Fanta C.H., Weinblatt M.E., O'Donnell W., and Coblyn J.S. Bronchiectasis-a late feature of severe rheumatoid arthritis. Medicine 73 3 (1994) 161-170
11. Swinson D.R., Symmons D., Suresh U., Jones M., and Booth J. Decreased survival in patients with co-existent rheumatoid arthritis and bronchiectasis. Br J Rheumatol 36 (1997) 689-691
12. Perez T., Remy-Jardin M., and Cortet B. Airways involvement in rheumatoid arthritis-clinical, functional and HRCT findings. Am J Respir Crit Care Med 157 (1998) 1658-1665
13. Cohen M., and Sahn S.A. Bronchiectasis in systemic diseases. Chest 116 (1999) 1063-1074
14. Ellerin T., Rubin R.H., and Weinblatt M.E. Infections and anti-tumor necrosis factor α therapy. Arthritis Rheum 48 11 (2002) 3013-3022
15. Hyrich K.L., Silman A.J., Watson K.D., and Symmons D.P.M. Anti-tumor necrosis factor α therapy in rheumatoid arthritis. an update on safety. Ann Rheum Dis 63 (2004) 1538-1543
16. Cush J.J. Safety Overview of new disease-modifying antirheumatic drugs. Rheum Dis Clin N Am 30 (2004) 237-255
17. Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340 4 (1999) 253-259
18. Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343 22 (2000) 1586-1593
19. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum 46 6 (2002) 1443-1450
20. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis. double blind randomized controlled trial. Lancet 363 9410 (2004) 675-681
21. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41 9 (1998) 1552-1563
22. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate. a randomized phase III trial. Lancet 354 9194 (1999) 1932-1939
23. Lipsky P.E., van der Heijde D., St. Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343 22 (2000) 1594-1602
24. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Durst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 50 4 (2004) 1051-1065
25. St. Clair E.W., van der Heijde D., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. Arthritis Rheum 50 11 (2004) 3432-3443
26. Drevlow B.E., Lovis R., Haag M.A., Sinacore J.M., Jacobs C., Blosche C., et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 39 2 (1996) 257-265
27. Campion G.V., Lebsack M.E., Lookabaugh J., Gordon G., and Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 39 7 (1996) 1092-1101
28. Bresnihan B., Alvaro-Garcia J.M., Cobby M., Doherty M., Domljan Z., Emery P., et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41 12 (1998) 2196-2204
29. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate (The Armada Trial). Arthritis Rheum 48 1 (2003) 35-45
30. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis. results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30 12 (2003) 2563-2571
31. Van de Putte L.B.A., Rau R., Breedveld F.C., Kalden J.R., Malaise M.G., van Riel P.L.C.M., et al. Efficacy and safety of the fully human anti-tumor necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis. a 12 week, phase II study. Ann Rheum Dis 62 (2003) 1168-1177
32. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 50 5 (2004) 1400-1411
33. Cortet B., Flipo R.M., Remy-Hardin M., Coquerelle P., Duquesnoy B., Remy J., et al. Use of high resolution computed tomography of the lungs in patients with rheumatoid arthritis. Ann Rheumatic Dis 54 10 (1995) 815-819
34. Hillarby M.C., McMahon M.J., Grennan D.M., Cooper R.G., Clarkson R.W.E., Davies E.J., et al. HLA Associations in subjects with rheumatoid arthritis and bronchiectasis but not with other pulmonary complications of rheumatoid disease. Br J Rheumatol 32 (1993) 794-797
35. Reid L.M. Reduction in bronchial subdivision in bronchiectasis. Thorax 5 (1950) 223-247
36. Delen F.M., and Barker A.F. New Concepts in diagnosis and management of bronchiectasis. Semin Respir Crit Care Med 20 4 (1999) 311-320
37. Angrill J., Agusti C., de Celis R., Fillela X., Rano A., Elena M., et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 164 (2001) 1628-1632
38. Schaaf B., Weighorst A., Aries S.P., Dalhoff K., and Braun J. Neutrophil inflammation and activation in bronchiectasis. comparison with pneumonia and idiopathic pulmonary fibrosis. Respiration 67 (2000) 5259
39. Stockley R.A., Shaw J., Hill S.L., and Burnett D. Neutrophil chemotaxis in bronchiectasis. a study of peripheral cells and lung secretions. Clin Sci 74 (1998) 645-650
40. Hansell D.M. Bronchiectasis. Radiol Clin North Am 36 1 (1998) 107-128
41. King P.T., Holdsworth S.R., Freezes N.J., Villanueva E., Gallagher M., and Holmes P.W. Outcome in adult bronchiectasis. J COPD 2 (2005) 27-34